Pay in 4 interest-free payments of $6.19 Learn more
Ships within 48 hours · Estimated delivery Nov 6 - Nov 11
The FDA approval provides another layer of reassurance that this is the right therapy, and it opens the door for broader insurance coverage making treatment more accessible for patients who need it most
This included testing for factor V Leiden mutation, prothrombin gene mutation, protein C level, protein S level, antithrombin level, ANA, lupus anticoagulant, anticardiolipin antibody, beta 2 glycoprotein, and D-dimer level
Its contraindicated in patients with hemorrhagic disorders, peptic ulcer disease, cerebral hemorrhage, trauma, and recent eye or nervous system surgeries
It's important to note that while AOD9604 shows promise, further large-scale human clinical trials are necessary to fully establish its efficacy and long-term safety profile
Since each patient is different, a customized approach is recommended
